news

CUPERTINO, Calif., July 6 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced the advancement of its ORADUR(TM) sustained release oral gel-cap technology (formerly referred to as the SABER(TM) oral gel-cap technology) with positive human clinical results for Remoxy(TM). Remoxy is a novel long-acting oral formulation of oxycodone based on DURECT’s ORADUR technology under development by Pain […]

CUPERTINO, Calif., and VALENCIA, Calif., June 21 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) and NeuroSystec Corporation (“NeuroSystec”), a privately held company located in Valencia, CA, announced today that they have signed an exclusive agreement to develop, market and sell products for the treatment of certain inner ear disorders including chronic tinnitus (ringing in the ears).

CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest Global Healthcare Conference at 3:30 PM local time (10:30 AM, Eastern Daylight Time) on Wednesday, May 12, 2004 in London, England. Presenting for the company will be Thomas A. Schreck, Chief Financial Officer

CUPERTINO, Calif., April 27 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 27-28th at The Millennium Broadway Hotel in New York City, New York. James E. Brown, DVM, President and Chief Executive Officer will

CUPERTINO, Calif., April 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2004. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended March 31, 2004 was $6.0 million or 12 cents per share, compared to a net loss of $5.9 million or 12 cents

CUPERTINO, Calif., Apr 14, 2004 /PRNewswire-FirstCall via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, April 22, 2004 at 4:30 p.m. EDT with Jim Brown, President and Chief

CUPERTINO, Calif., Mar 23, 2004 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael D. Casey to its Board of Directors to replace John L. Doyle who left the Board in November 2003. The appointment of Mr. Casey maintains the current DURECT Corporation Board membership at eight. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

CUPERTINO, Calif., Feb. 24 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Smith Barney Citigroup Specialty Pharmaceuticals Conference. The conference is taking place February 24-25th at The Marriott East Side Hotel in New York City, New York. Dr. James E. Brown, President and Chief Executive Officer will be presenting

CUPERTINO, Calif., Feb. 13 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Su IL Yum has been promoted to Senior Vice President of Engineering. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “We are very fortunate to have Su IL to help us through these formative years at DURECT, where he is able to guide the development of

CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2003. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended December 31, 2003 was $5.3 million or 10 cents per share, compared to a net loss of $8.5 million